Drug intelligence / Profile preview

JNJ-69095897

Development stage: Unknown
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-69095897 is an investigational small molecule drug developed by Johnson & Johnson. It acts as an inhibitor of monoacylglycerol lipase (MAGL), a key enzyme involved in the degradation of endocannabinoids, which play roles in pain, inflammation, and neurological processes. The drug was studied for its safety, tolerability, and pharmacokinetics after oral administration in healthy volunteers. Clinical development reached Phase 1 but was terminated without progression to further phases or approval for any indication[1][2][3].

Targets

MGLL (Monoacylglycerol lipase)

Beyond the preview

Go deeper on JNJ-69095897.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-69095897.

Explore the full profile